<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6302212</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.02971</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Prevalence and Significance of Non-conventional Antiphospholipid Antibodies in Patients With Clinical APS Criteria </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Litvinova</surname><given-names>Elena</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/603178/overview"/></contrib><contrib contrib-type="author"><name><surname>Darnige</surname><given-names>Luc</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/595340/overview"/></contrib><contrib contrib-type="author"><name><surname>Kirilovsky</surname><given-names>Amos</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/615695/overview"/></contrib><contrib contrib-type="author"><name><surname>Burnel</surname><given-names>YANN</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Luna</surname><given-names>Gonzalo</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Dragon-Durey</surname><given-names>Marie-Agnes</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/526506/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Laboratory of Immunology, HEGP, APHP</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Biological Haematology, HEGP, APHP</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><aff id="aff3"><sup>3</sup><institution>Inserm UMR-S1140</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><aff id="aff4"><sup>4</sup><institution>Paris Descartes University</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><aff id="aff5"><sup>5</sup><institution>Immunomonitoring Plateform, HEGP, APHP</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><aff id="aff6"><sup>6</sup><institution>Internal Medicine Department, HEGP, APHP</institution>, <addr-line>Paris</addr-line>, <country>France</country></aff><author-notes><fn fn-type="edited-by"><p><text><SENT sid="1" pm="."><plain>Edited by: Jean-Christophe Raymond Gris, Centre Hospitalier Universitaire de Nîmes, France </plain></SENT>
</text></p></fn><fn fn-type="edited-by"><p><text><SENT sid="2" pm="."><plain>Reviewed by: Deepika Sharma, University of Chicago, United States; Marie Cohen, Université de Genève, Switzerland </plain></SENT>
</text></p></fn><corresp id="c001">*Correspondence: Marie-Agnes Dragon-Durey <email>marie-agnes.durey@aphp.fr</email></corresp><fn fn-type="other" id="fn001"><p><text><SENT sid="3" pm="."><plain>This article was submitted to Autoimmune and Autoinflammatory Disorders, a section of the journal Frontiers in Immunology </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>2971</elocation-id><history><date date-type="received"><day>31</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>03</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 Litvinova, Darnige, Kirilovsky, Burnel, de Luna and Dragon-Durey.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Litvinova, Darnige, Kirilovsky, Burnel, de Luna and Dragon-Durey</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>Background: The biological diagnostics of antiphospholipid syndrome (APS) takes into account the persistent positivity for anticardiolipin and/or anti-β2GP1 antibodies and/or presence of lupus anticoagulant (LA). </plain></SENT>
<SENT sid="5" pm="."><plain>However, some non-conventional antiphospholipid antibodies have emerged that could help in the diagnosis of APS. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="6" pm="."><plain>Objectives: To study the potential usefulness of non-conventional antiphospholipid antibodies in clinical practice. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="7" pm="."><plain>Methods: Eighty-seven patients, aged from 15 to 92 years were included and classified in following groups: 41 patients positive for the conventional antibodies with clinical criterion of APS (31 with primary APS and 10 secondary), 17 seronegative APS (SNAPS) patients (i.e., persistent negativity for the conventional antibodies with a strong clinical suspicion of APS), 11 asymptomatic antiphospholipid antibodies carriers (i.e., persistent positivity for the conventional antibodies without clinical evidence of APS), and 18 patients presenting with a first thrombotic or obstetrical event. </plain></SENT>
<SENT sid="8" pm="."><plain>IgG and IgM were detected to the following antigens: phosphatidylserine/prothrombin (PS/PT) by ELISA, and phosphatidic acid, phosphatidyl-ethanolamine, phosphatidyl-glycerol, phosphatidyl-inositol, phosphatidylserine, annexin V, prothrombin by immunodot. </plain></SENT>
<SENT sid="9" pm="."><plain>Anti-β2GP1 IgA, and anti-β2GP1 domain 1 IgG were detected by chemiluminescence. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="10" pm="."><plain>Results: Positivity for the non-conventional antibodies was correlated with APS severity; patients with catastrophic APS (CAPS) being positive for 10.7 (Median, Range: 5–14) non-conventional antibodies. </plain></SENT>
<SENT sid="11" pm="."><plain>9/17 seronegative patients were positive for at least one of non-conventional antibodies. </plain></SENT>
<SENT sid="12" pm="."><plain>A study of non-supervised hierarchical clustering of all markers revealed that anti-PS/PT antibodies showed high correlation with the presence of LA. </plain></SENT>
<SENT sid="13" pm="."><plain>All patients with APS triple positivity (highest risk profile) exhibited also persistent positivity for anti-PS/PT antibodies. </plain></SENT>
</text></SecTag></p><p><SecTag type="ABS"><text><SENT sid="14" pm="."><plain>Conclusions: Our data obtained from a prospective cohort constituted mainly by patients with primary APS, suggest that non-conventional APS antibodies may be useful for patients classified as SNAPS. </plain></SENT>
<SENT sid="15" pm="."><plain>They demonstrate the potential value of aPS/PT antibodies as a strong marker of APS. </plain></SENT>
<SENT sid="16" pm="."><plain>We propose that anti-PS/PT antibodies could be a surrogate APS biological marker of LA to classify in high-risk profile patients treated by direct oral anticoagulants (DOACs), in whom LA detection cannot be achieved. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><kwd>antiphospholipid syndrome</kwd><kwd>autoantibodies</kwd><kwd>anti-phosphatidylserine-prothrombin antibodies</kwd><kwd>lupus anticoagulant</kwd><kwd>thrombosis</kwd></kwd-group></SecTag><counts><fig-count count="4"/><table-count count="3"/><equation-count count="0"/><ref-count count="44"/><page-count count="10"/><word-count count="6743"/></counts></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s1"><title><text><SENT sid="17" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="18" pm="."><plain>The antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombotic and/or obstetrical manifestations associated with the persistent positivity for at least one of three markers: lupus anticoagulant (LA), anti-cardiolipin antibodies (aCL) or anti-beta2-glycoprotein I (aβ2GP1) antibodies of either IgG or IgM isotype (1, 2). </plain></SENT>
</text></p><p><text><SENT sid="19" pm="."><plain>The prevalence of APS is estimated at around 40–50 cases per 100,000 persons (3). </plain></SENT>
<SENT sid="20" pm="."><plain>APS can be primary, i.e., without any other definable disease, or secondary, i.e., associated with other diseases, the most often being systemic lupus erythematosus (4). </plain></SENT>
<SENT sid="21" pm="."><plain>According to the site of thrombosis and the number and size of vessels involved, APS has different kinds of clinical manifestations such as peripheral thrombosis, neurological, pulmonary, cardiac or obstetric manifestations (recurrent fetal losses or intra utero growth retardation) (5). </plain></SENT>
<SENT sid="22" pm="."><plain>The most severe form of APS, called catastrophic APS (CAPS) is characterized by multiorgan failure due to diffuse thrombotic microvasculopathy (6, 7), and counts for &lt; 1% of APS (5). </plain></SENT>
</text></p><p><text><SENT sid="23" pm="."><plain>Secondary prevention of thrombosis is based on a long-term anticoagulation therapy (8). </plain></SENT>
<SENT sid="24" pm="."><plain>In some severe cases, rituximab may be indicated (9). </plain></SENT>
<SENT sid="25" pm="."><plain>The treatment of CAPS requires an aggressive therapy using anticoagulation associated with high-dose steroids, plasma exchange or intravenous immunoglobulin (10). </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Considering its high rate of thrombotic recurrence that may be efficiently prevented by prophylactic anticoagulant therapy, an accurate identification of patients with APS is crucial. </plain></SENT>
<SENT sid="27" pm="."><plain>Also, treatment of APS women during pregnancy leads to a very significant improvement of fetal and maternal outcomes (11, 12). </plain></SENT>
</text></p><p><text><SENT sid="28" pm="."><plain>Despite progresses in the treatment, patients with APS still develop significant morbidity and mortality (13, 14), and rapid diagnosis and treatment as well as the determination of reliable prognostic markers are of ultimate importance. </plain></SENT>
</text></p><p><text><SENT sid="29" pm="."><plain>Antiphospholipid antibodies (APA) are constituted by a heterogeneous group of autoantibodies directed against anionic phospholipids, phospholipid-binding plasma proteins or protein-phospholipid complexes (15). </plain></SENT>
<SENT sid="30" pm="."><plain>Apart from conventional biological markers (LA, aCL and aβ2GP1), numerous other markers of APS have been studied such as antibodies against phosphatidyl-ethanolamine (16), phosphatidylserine-prothrombin (17), that could be helpful in the diagnosis of so-called seronegative APS (SNAPS) (18, 19), which defines a group of patients with clinical manifestations of APS but with persistently negative aCL, aβ2GP1 antibodies and LA. </plain></SENT>
<SENT sid="31" pm="."><plain>Furthermore, the study of the autoantibodies' epitope specificities revealed that the β2GP1 domain I is the most specific target of APS (20). </plain></SENT>
<SENT sid="32" pm="."><plain>In addition, antibodies of IgA isotype, mainly against β2GP1, have been suggested as a new marker in SNAPS patients (21, 22). </plain></SENT>
</text></p><p><text><SENT sid="33" pm="."><plain>In recent years, direct oral anticoagulants (DOACs) therapies directly inhibiting thrombin or factor Xa are used more frequently and many studies have shown that these drugs may influence LA testing. </plain></SENT>
<SENT sid="34" pm="."><plain>DOACs induce false positive results of LA detection even when their concentration is very low. </plain></SENT>
<SENT sid="35" pm="."><plain>Therefore, LA testing should not be performed during treatment with DOACs (23). </plain></SENT>
<SENT sid="36" pm="."><plain>LA is the conventional biological marker associated with the strongest risk for thrombosis and other clinical APS manifestations. </plain></SENT>
<SENT sid="37" pm="."><plain>Moreover, it has been demonstrated that triple positivity for conventional markers in APS patients or in asymptomatic APA carriers is associated with significantly higher risk of thrombosis than single or double positivity (24, 25). </plain></SENT>
<SENT sid="38" pm="."><plain>LA testing in patients treated by DOACS would necessitate discontinuing the treatment for at least 3 days but it may be unsafe. </plain></SENT>
<SENT sid="39" pm="."><plain>Interestingly, presence of anti-phosphatidylserine/prothrombin antibodies has been shown to be closely associated with presence of LA (26). </plain></SENT>
</text></p><p><text><SENT sid="40" pm="."><plain>In this study, we aimed to explore the usefulness of several non-conventional APS markers for the diagnosis of patients with clinical manifestations of APS and SNAPS. </plain></SENT>
<SENT sid="41" pm="."><plain>We also wondered if anti-phosphatidylserine-prothrombin antibodies could replace the use of LA testing in patients treated with DOACs. </plain></SENT>
<SENT sid="42" pm="."><plain>Presence and persistence of 10 non-conventional APS markers have been studied prospectively in patients presenting with APS or thrombosis and in healthy donors. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="materials and methods" id="s2"><title><text><SENT sid="43" pm="."><plain>Materials and Methods </plain></SENT>
</text></title><sec><title><text><SENT sid="44" pm="."><plain>Patients </plain></SENT>
</text></title><p><text><SENT sid="45" pm="."><plain>Eighty seven patients were included prospectively between September 2015 and May 2017. </plain></SENT>
<SENT sid="46" pm="."><plain>Patients were aged from 15 to 92 years old and comprised of 50 women and 37 men (Table 1). </plain></SENT>
<SENT sid="47" pm="."><plain>Additionally, a group of 30 healthy donors (HD) was used as controls. </plain></SENT>
<SENT sid="48" pm="."><plain>The study was done in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. </plain></SENT>
<SENT sid="49" pm="."><plain>No additional sample from the patients was collected for the study. </plain></SENT>
<SENT sid="50" pm="."><plain>All patients were seen in the context of their routine care, clinically evaluated and informed about the study and about the computerization of personal health data by the same physician (LD) during the follow up of the study. </plain></SENT>
<SENT sid="51" pm="."><plain>The patients gave oral informed consent in accordance with French legal standards for observational studies. </plain></SENT>
<SENT sid="52" pm="."><plain>This study has been approved by the Institutional Review Board according to standards currently applied in France (Commission Nationale de l'Informatique et des Libertés”, CNIL N°1922081 from 02/02/2016). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" position="float"><label>Table 1</label><caption><p><text><SENT sid="53" pm="."><plain>Patients' characteristics. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="54" pm="."><plain>Frequency (number) </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="2" style="background-color:#bdbec1" rowspan="1"><text><SENT sid="55" pm="."><plain>AGE (YEARS) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="56" pm="."><plain> 15–30 31–60 61–92 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="57" pm="."><plain>15% (13) 66% (57) 19% (17) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" colspan="2" style="background-color:#bdbec1" rowspan="1"><text><SENT sid="58" pm="."><plain>SEX </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="59" pm="."><plain>Females Males </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="60" pm="."><plain>57% (50) 43% (37) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" colspan="2" style="background-color:#bdbec1" rowspan="1"><text><SENT sid="61" pm="."><plain>DISEASE GROUP: </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="62" pm="."><plain>1. </plain></SENT>
<SENT sid="63" pm="."><plain>APS </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="64" pm="."><plain>47% (41) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1"><text><SENT sid="65" pm="."><plain>According to clinical signs: </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="66" pm="."><plain>Thrombosis:     CAPS     Arterial     Venous     Both Obstetrical morbidity only </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="67" pm="."><plain>88% (36) (3) (10) (21) (2) 12% (5) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1"><text><SENT sid="68" pm="."><plain>According to number of conventional biological markers: </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="69" pm="."><plain>With 1 biomarker With 2 biomarkers With 3 biomarkers </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="70" pm="."><plain>32% (13) 24% (10) 44% (18) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="71" pm="."><plain>Primary or secondary: </plain></SENT>
</text></td><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="72" pm="."><plain>Primary Associated with lupus Associated with Autoimmune Hepatitis </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="73" pm="."><plain>76% (31) 22% (9) 2% (1) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="74" pm="."><plain>2. </plain></SENT>
<SENT sid="75" pm="."><plain>SNAPS    Thrombosis:     Arterial     Venous     Both     Obstetrical complications3. </plain></SENT>
<SENT sid="76" pm="."><plain>Asymptomatic APA carriers 4. </plain></SENT>
<SENT sid="77" pm="."><plain>First Thrombotic/obstetrical event:    Arterial     Venous     Both     Obstetrical </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="78" pm="."><plain>20% (17) 56% (9) (1) (7) (1) 44% (8) 13% (11) 22% (18) (6) (10) (1) (1) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="79" pm="."><plain>APS, Anti-phospholipid syndrome; CAPS, Catastrophic anti-phospholipid syndrome; SNAPS, Seronegative anti-phospholipid syndrome; APA, Anti-phospholipid antibodies. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="80" pm="."><plain>Blood samples were collected and sera were analyzed. </plain></SENT>
<SENT sid="81" pm="."><plain>According to the clinical data and to the biological parameters, the patients were classified into the following groups: (1) APS; (2) SNAPS, i.e., patients with strong clinical suspicion of APS but persistently negative for conventional biological markers; (3) asymptomatic antiphospholipid antibodies (APA) carriers, i.e., clinically asymptomatic individuals presenting with persistent antiphospholipid antibodies positivity (discovered fortuitously, mostly during preoperative assessment of hemostasis); (4) first thrombotic event and/or obstetrical morbidity group, i.e., patients presenting with a first thrombotic or obstetrical event. </plain></SENT>
</text></p><p><text><SENT sid="82" pm="."><plain>Patients were classified according to the type of clinical feature: arterial thrombosis, venous thrombosis, both, obstetrical complications or CAPS (Table 1). </plain></SENT>
</text></p><p><text><SENT sid="83" pm="."><plain>Our APS cohort is composed by a majority (76%, n = 31) of patients presenting with primary APS whereas 24% had an APS secondary to lupus (9 patients) or other autoimmune disease [autoimmune hepatitis: 1 patient] (Table 1). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="84" pm="."><plain>Methods </plain></SENT>
</text></title><p><text><SENT sid="85" pm="."><plain>The two different coagulation tests used to detect lupus anticoagulant (LA) according to ISTH recommendations (27) were: dilute Russell venom viper time (dRVVT) using LA1 reagents (Siemens, Germany) and aPTT using Automated APTT (Trinity Biotech, Ireland).The phospholipid dependence was confirmed by positive phospholipid-neutralizing assays for both tests with a dRVVT screen (LA1 reagent)/confirm (LA2 reagent, Siemens, Germany) ratio and a ratio of aPTT with silica (LA sensitive reagent)/Kaolin PTT (LA insensitive reagent, CK Prest, Stago, France). </plain></SENT>
</text></p><p><text><SENT sid="86" pm="."><plain>Anti-CL and aβ2GP1 antibodies of IgG isotype were detected in the serum by the routinely used ELISA methods: Cardiolisa, (Theradiag, Croissy-Beaubourg, France) and QUANTA Lite® β2 GP1 IgG (Inova Diagnostics Werfen, Les Lilas, France). </plain></SENT>
<SENT sid="87" pm="."><plain>Anti-CL and aβ2GP1 antibodies of IgM isotype were detected by the immunodot technique (Cf below). </plain></SENT>
</text></p><p><text><SENT sid="88" pm="."><plain>Anti-phosphatidylserine-prothrombin (aPS/PT) antibodies of IgM and IgG isotypes were measured in the serum by ELISA (Quanta Lite, INOVA Diagnostics, Werfen, Les Lilas, France). </plain></SENT>
</text></p><p><text><SENT sid="89" pm="."><plain>The immunodot technique (Anti-Phospholipid 10 Dot, Generic Assays, Eurobio, Les Ulis, France) was performed in the serum using the BlueDiver Instrument (D-Tek, Ingen, Chilly Mazarin, France) allowing the detection of IgG and IgM antibodies directed against the following antigens: CL, β2GP1, phosphatidic acid (PA), phosphatidyl-ethanolamine (PE), phosphatidyl-glycerol (PG), phosphatidyl-inositol (PI), phosphatidylserine (PS), annexin V (A5), and prothrombin (PT). </plain></SENT>
</text></p><p><text><SENT sid="90" pm="."><plain>Anti-β2GP1of IgA isotype and aβ2GP1 domain I antibodies were measured in the serum by BIO-FLASH Chemiluminescent Immuno Assay technology (QUANTA Flash® β2 GP1 IgA Inova Diagnostics Werfen, Les Lilas, France). </plain></SENT>
</text></p><p><text><SENT sid="91" pm="."><plain>Prism and Medcalc Softwares were used for the statistical analysis and Genesis software (version 1.8.1) was used to perform the hierarchical clustering of APS biomarkers. </plain></SENT>
<SENT sid="92" pm="."><plain>The titers of APL antibodies were compared using Mann-Whitney-Wilcoxon test. </plain></SENT>
<SENT sid="93" pm="."><plain>Correlation between the presences of different antibodies was measured by Kendall correlation using the software R version 3.4.4 [R (28)] and the package ggcorrplot version 0.1.1 (29). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s3"><title><text><SENT sid="94" pm="."><plain>Results </plain></SENT>
</text></title><sec><title><text><SENT sid="95" pm="."><plain>Results of Classical APS Markers </plain></SENT>
</text></title><p><text><SENT sid="96" pm="."><plain>The distribution and prevalence of the classical APS markers in our cohort are depicted in the Supplementary Figure 1. </plain></SENT>
</text></p><p><text><SENT sid="97" pm="."><plain>Presence of aCL antibodies was detected in 95% patients with APS and in 45% in the group of asymptomatic APA carriers but was not detectable in the group of SNAPS and thrombosis/obstetric (Supplementary Table 1). </plain></SENT>
<SENT sid="98" pm="."><plain>Their levels were significantly higher in the APS patients with three conventional biomarkers than in the other patients' groups (Supplementary Figure 1A). </plain></SENT>
</text></p><p><text><SENT sid="99" pm="."><plain>Presence of aβ2GP1 was detected in 51% of patients with APS and in 18% of patients from the group of asymptomatic APA carriers and was not detectable in the group of SNAPS and thrombosis/obstetric. </plain></SENT>
<SENT sid="100" pm="."><plain>IgG aβ2GP1 positivity was observed almost only in the group of APS patients with 3 biomarkers (Supplementary Figure 1B). </plain></SENT>
<SENT sid="101" pm="."><plain>The patients presenting with CAPS exhibited the highest titers of aCL and aβ2GP1 antibodies (Supplementary Figures 1C,D). </plain></SENT>
</text></p><p><text><SENT sid="102" pm="."><plain>LA positivity was observed in 68% of APS patients and in 100% of patients from the group of asymptomatic APA carriers and was not detectable in the group of SNAPS and thrombosis/obstetric. </plain></SENT>
<SENT sid="103" pm="."><plain>Its prevalence in different groups of patients is shown in the Supplementary Table 1. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="104" pm="."><plain>Results of aPS/PT Antibodies </plain></SENT>
</text></title><p><text><SENT sid="105" pm="."><plain>Anti-PS/PT antibodies of IgG and IgM isotypes were measured in all groups of patients and controls. </plain></SENT>
</text></p><p><text><SENT sid="106" pm="."><plain>Presence of IgG aPS/PT was detected in 43.9% of patients in the group of APS, 5.6% in the group of SNAPS, 18.2% in the group of asymptomatic APA carriers. </plain></SENT>
<SENT sid="107" pm="."><plain>It was not detectable in the group of thrombosis/obstetric and in HD. </plain></SENT>
<SENT sid="108" pm="."><plain>Their levels were significantly higher in the APS patients with two and three biomarkers than in the other groups of patients (Figure 1A). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F1" position="float"><label>Figure 1</label><caption><p><text><SENT sid="109" pm="."><plain>Results of anti-PS/PT antibodies. </plain></SENT>
<SENT sid="110" pm="."><plain>The distribution of anti-PS/PT IgG or IgM antibodies is shown in all groups of patients and in HD (A,B according to the disease group; C,D according to the clinical type of APS). </plain></SENT>
<SENT sid="111" pm="."><plain>The positive thresholds (30 AU/mlAU/ml) are shown by dotted lines. (A,C) aPS/PT antibodies of IgG isotype, (B, D) aPS/PT antibodies of IgM isotype. </plain></SENT>
<SENT sid="112" pm="."><plain>The data are presented as mean ± s.e.m. with all individual dots shown. </plain></SENT>
<SENT sid="113" pm="."><plain>The p-values were calculated using Mann-Whitney test. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001. HD, Healthy Donors; SNAPS, seronegative anti-phospholipid syndrome; Asympt APA, asymptomatic carriers of antiphospholipid antibodies; APS 1 BM, APS with 1 biomarker; APS 2 BM, APS with 2 biomarkers; APS 3 BM, APS with 3 biomarkers; V thromb, venous thrombosis; Art thromb, arterial thrombosis; Obst APS, obstetrical APS; CAPS, Catastrophic anti-phospholipid syndrome. </plain></SENT>
</text></p></caption><graphic xlink:href="fimmu-09-02971-g0001"/></fig></SecTag><p><text><SENT sid="114" pm="."><plain>Presence of IgM aPS/PT was detected 65.8% in the group of APS, 16.7% in the group of SNAPS, 81.8% in the group of asymptomatic APA carriers, 5.3% in the group of thrombosis/ obstetric, and 6.7% in HD. </plain></SENT>
<SENT sid="115" pm="."><plain>Their levels were significantly higher in the groups of APS with two and three biomarkers but also in the group of asymptomatic APA carriers as compared to the other groups (Figure 1B). </plain></SENT>
</text></p><p><text><SENT sid="116" pm="."><plain>The comparison of the levels of aPS/PT antibodies in APS patients according to the different types of thrombosis, showed significant differences between HD and APS patients with venous thrombosis, obstetrical morbidity and CAPS for IgG isotype (Figure 1C). </plain></SENT>
<SENT sid="117" pm="."><plain>For IgM isotype significant differences were observed between HD and APS patients with venous thrombosis and CAPS (Figure 1D). </plain></SENT>
<SENT sid="118" pm="."><plain>Patients with CAPS had statistically significant higher levels of IgG aPS/PT antibodies than patients with arterial thrombosis (p = 0.029, Figure 1C). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="119" pm="."><plain>Results of aβ2GP1 Antibodies of IgA Isotype and aβ2GP I Domain I Antibodies of IgG Isotype </plain></SENT>
</text></title><p><text><SENT sid="120" pm="."><plain>IgA aβ2GP1 were found only in patients with APS with two (31.6%) or three biomarkers (60.9%) and were negative in the other groups (Figure 2A). </plain></SENT>
<SENT sid="121" pm="."><plain>The levels of IgA aβ2GP1 were significantly higher in the group of APS patients with three biomarkers than those with two biomarkers (p = 0.0002). </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F2" position="float"><label>Figure 2</label><caption><p><text><SENT sid="122" pm="."><plain>Results of anti-β2GP1 IgA and anti- β2GP1 D1 IgG antibodies. </plain></SENT>
<SENT sid="123" pm="."><plain>The distribution of IgA aβ2GP1 and aβ2GP1 D1 antibodies is shown in all groups of patients and in HD (A,B according to the disease group; C,D according to the clinical type of APS). </plain></SENT>
<SENT sid="124" pm="."><plain>The data are presented as mean ± s.e.m. with all individual dots shown. </plain></SENT>
<SENT sid="125" pm="."><plain>The p-values were calculated using Mann–Whitney test. *p &lt; 0.05; **p &lt; 0.01; ***p &lt; 0.001. </plain></SENT>
<SENT sid="126" pm="."><plain>The limit of positivity for IgA aβ2GP1 (20 AU/ml) is shown by the dotted line (A,C). </plain></SENT>
<SENT sid="127" pm="."><plain>The limit of positivity for aβ2GP1 D1 is 20 lAU/ml (not shown) (B,D). (A) Statistical differences are significant between APS 3 BM and all other groups (p &lt; 0.001). (B) In addition to differences shown in the graph, statistical differences are significant between APS 3 BM, and APS 2 BM (p &lt; 0.01) and between APS 3 BM and all other groups (p &lt; 0.001). HD, Healthy Donors; SNAPS, seronegative anti-phospholipid syndrome; Asympt APA, asymptomatic carriers of antiphospholipid antibodies; APS 1 BM, APS with 1 biomarker; APS 2 BM, APS with 2 biomarkers; APS 3 BM, APS with 3 biomarkers; V thromb, venous thrombosis; Art thromb, arterial thrombosis; Obst APS, obstetrical APS; CAPS, Catastrophic anti-phospholipid syndrome. </plain></SENT>
</text></p></caption><graphic xlink:href="fimmu-09-02971-g0002"/></fig></SecTag><p><text><SENT sid="128" pm="."><plain>IgG aβ2GP1 domain I (aβ2GP1 D1) were detected in 50% in the group of APS and in 11.1% in the group of asymptomatic APA carriers but were not detectable in the groups of SNAPS, thrombosis/obstetric and in HD (Figure 2B). </plain></SENT>
<SENT sid="129" pm="."><plain>Their levels were higher in the APS patients with triple positivity than those observed in patients with two biomarkers (mean = 571 vs. mean = 82 AU/ml, p = 0.0027). </plain></SENT>
<SENT sid="130" pm="."><plain>Of note, one patient from the asymptomatic APA carriers' group was highly positive for aβ2GP1 D1 (314 AU/ml, normal values &lt; 20 AU/ml). </plain></SENT>
</text></p><p><text><SENT sid="131" pm="."><plain>No correlation was found between the clinical type of APS and level of these antibodies but in CAPS patients the level of IgA aβ2GP1 was significantly higher than in patients with obstetrical APS (Figure 2C) and the level of aD1 β2GP1 in CAPS was significantly higher than in patients with venous thrombosis (Figure 2D). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="132" pm="."><plain>Frequency and Distribution of Other Non-conventional APS Antibodies Tested by Immunodot </plain></SENT>
</text></title><p><text><SENT sid="133" pm="."><plain>Presence of other non-conventional markers of APS was searched in serum from all groups of patients and from healthy donors by a semi-quantitative analysis (immunodot). </plain></SENT>
</text></p><p><text><SENT sid="134" pm="."><plain>A higher frequency of positivity or titer in patients compared to HD was observed for IgG directed against PG, PA, PI, PS, and for IgM anti-PI, PS, PA, and PT (Supplementary Figure 2). </plain></SENT>
<SENT sid="135" pm="."><plain>No positivity was observed for anti-PE IgG and IgM. </plain></SENT>
</text></p><p><text><SENT sid="136" pm="."><plain>The Figure 3 shows the mean number of positive markers per patient for each group, compared to the HD. </plain></SENT>
<SENT sid="137" pm="."><plain>In the group of thrombosis, in patients with SNAPS and in the asymptomatic patients with APA, the number of positive markers was inferior or equal to one per patient whereas in APS patients it was from 2 to 6 per patient. </plain></SENT>
<SENT sid="138" pm="."><plain>The highest number of positive markers was observed in the group of CAPS with a mean of 6.3 IgG or IgM markers per patient when aPS/PT antibodies are excluded, and 10.7 (range from 5 to 14) markers per patient when aPS/PT are included in the analysis. </plain></SENT>
<SENT sid="139" pm="."><plain>All patients with CAPS were positive for anti-PA and anti-PS IgG antibodies and 2 from 3 patients for anti-PG and anti-PI IgG antibodies. </plain></SENT>
<SENT sid="140" pm="."><plain>Antibodies of IgM isotype were less frequent in CAPS patients. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F3" position="float"><label>Figure 3</label><caption><p><text><SENT sid="141" pm="."><plain>Frequency of other APS non-conventional markers in the different groups of patients and HD. </plain></SENT>
<SENT sid="142" pm="."><plain>Non-conventional APS markers of IgG and IgM isotypes were detected by immunodot technique in sera of different groups of patients and in HD. </plain></SENT>
<SENT sid="143" pm="."><plain>Y ax shows a mean of positive markers (PA, PG, PI, PS, A5, and PT of IgG and IgM isotypes) per patient in each group. HD, Healthy Donors; SNAPS, seronegative anti-phospholipid syndrome; Asympt APA, asymptomatic carriers of antiphospholipid antibodies; APS 1 BM, APS with 1 biomarker; APS 2 BM, APS with 2 biomarkers; APS 3 BM, APS with 3 biomarkers; V thromb, venous thrombosis; Art thromb, arterial thrombosis; Obst APS, obstetrical APS; CAPS, Catastrophic anti-phospholipid syndrome; Pos, positive. </plain></SENT>
</text></p></caption><graphic xlink:href="fimmu-09-02971-g0003"/></fig></SecTag></sec><sec><title><text><SENT sid="144" pm="."><plain>Correlation Between the Different Non-conventional Markers </plain></SENT>
</text></title><p><text><SENT sid="145" pm="."><plain>In APS patients, the highest correlation with conventional markers was observed for IgG directed to PA and PS. </plain></SENT>
<SENT sid="146" pm="."><plain>We observed a significant correlation between the presence of anti-PA and anti-PS antibodies (Spearman's coefficient of correlation is 0.78 for IgG and 0.75 for IgM), and between anti-PG and anti-PI antibodies (Spearman's coefficient of correlation: 0.84 for IgG and 0.6 for IgM). </plain></SENT>
<SENT sid="147" pm="."><plain>A significant correlation was also observed between anti-PS, anti-PT, and anti-PS/PT IgM positivity but at lower degree (Spearman test &lt; 0.5, Supplementary Figure 3). </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="148" pm="."><plain>Clinical Performances of the Tests </plain></SENT>
</text></title><p><text><SENT sid="149" pm="."><plain>The Table 2 summarizes the results of positive and negative predictive values for clinical APS obtained for the aPS/PT, aB2GP1 IgA and aβ2GP1 D1 antibodies. </plain></SENT>
<SENT sid="150" pm="."><plain>The calculations were performed using a control group composed by the HD and asymptomatic APA carriers. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T2" position="float"><label>Table 2</label><caption><p><text><SENT sid="151" pm="."><plain>Clinical performances of non-conventional APS markers. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="152" pm="."><plain>a/β2GP1 IgA </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="153" pm="."><plain>a/β2GP1 domain I </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="154" pm="."><plain>a/PS PT IgG </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="155" pm="."><plain>a/PS PT IgM </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="156" pm="."><plain>PS/PT IgG+IgM </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="157" pm="."><plain>Sensitivity (%) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="158" pm="."><plain>38.5 (23.4–55.4) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="159" pm="."><plain>50 (33.4–66.6) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="160" pm="."><plain>43.9 (28.5–60.2) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="161" pm="."><plain>65.8 (49.4–79.9) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="162" pm="."><plain>43.9 (28.5–60.2) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="163" pm="."><plain>Specificity (%) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="164" pm="."><plain>100 (90.7–100) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="165" pm="."><plain>97.4 (86.5–99.9) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="166" pm="."><plain>95.1 (83.5–99.4) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="167" pm="."><plain>73.2 (57.1–85.8) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="168" pm="."><plain>97.6 (87.1–99.9) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="169" pm="."><plain>PPV (%) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="170" pm="."><plain>100 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="171" pm="."><plain>95 (72.8–99.3) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="172" pm="."><plain>90 (68.8–97.3) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="173" pm="."><plain>71 (58.6–81) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="174" pm="."><plain>94.7 (71.6–99.2) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="175" pm="."><plain>NPV (%) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="176" pm="."><plain>61.3 (55.3–67) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="177" pm="."><plain>66.7 (59.2–73.4) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="178" pm="."><plain>62.9 (56.2–69.2) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="179" pm="."><plain>68.2 (57.4–77.3) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="180" pm="."><plain>63.5 (56.9–69.6) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="181" pm="."><plain>PLR </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="182" pm="."><plain>NA </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>19.5 (2.74–138.5) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>9 (2.23–36.33) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>2.45 (1.41–4.26) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>18 (2.52–128.6) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>NLR </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>0.62 (0.48–0.79) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>0.51 (0.37–0.71) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>0.59 (0.45–0.78) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="191" pm="."><plain>0.47 (0.29–0.74) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain>0.58 (0.44–0.76) </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="193" pm="."><plain>Values are shown with 95% CI. </plain></SENT>
<SENT sid="194" pm="."><plain>For the calculations of predictive values the control group included HD, thrombosis/obstetric and asymptomatic APA groups. </plain></SENT>
<SENT sid="195" pm="."><plain>PPV, positive predictive value; NPV: negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="196" pm="."><plain>The aPS/PT antibodies of IgM isotype had the highest sensitivity, comparable to the LA sensitivity, while all antibodies of IgG isotype had high specificities. </plain></SENT>
<SENT sid="197" pm="."><plain>Negative likelihood ratio of aPS/PT antibodies of IgM isotype was the lowest (0.47) while the positive likelihood ratio value was the highest for aβ2GP1 D1 (19.5) and the combination of aPS/PT antibodies of IgG and IgM isotypes (18) (Table 2). </plain></SENT>
<SENT sid="198" pm="."><plain>The positive likelihood ratio could not be calculated for aβ2GP1 IgA antibodies as their specificity was 100%. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="199" pm="."><plain>Non-supervised Hierarchical Clustering of Conventional and Non-conventional APS Markers </plain></SENT>
</text></title><p><text><SENT sid="200" pm="."><plain>Genesis software v 1.8.1 (30) was used to perform a hierarchical clustering of all tested APS biomarkers in all groups of patients. </plain></SENT>
<SENT sid="201" pm="."><plain>We used a complete linkage approach and the distances of Pearson correlation. </plain></SENT>
<SENT sid="202" pm="."><plain>By this method we observed that aPS/PT antibodies of IgM isotype and LA were clustered together (Figure 4). </plain></SENT>
<SENT sid="203" pm="."><plain>The aPS/PT antibodies of IgG isotype and LA were also clustered in close proximity. </plain></SENT>
<SENT sid="204" pm="."><plain>In the group of asymptomatic APA carriers only aPS/PT antibodies of IgM isotype and LA were present, whereas in APS group aPS/PT antibodies of IgM isotype and LA were accompanied by aPS/PT antibodies of IgG isotype. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="F4" position="float"><label>Figure 4</label><caption><p><text><SENT sid="205" pm="."><plain>Hierarchical clustering of APS biomarkers using Genesis software. </plain></SENT>
<SENT sid="206" pm="."><plain>Unsupervised hierarchical clustering was performed, using Pearson correlation and complete linkage analysis. </plain></SENT>
<SENT sid="207" pm="."><plain>Each column corresponds to an APS marker. </plain></SENT>
<SENT sid="208" pm="."><plain>Each line corresponds to a patient with a number corresponding to the “disease group”: 1, Thrombosis; 2, SNAPS; 3, asymptomatic APA carrier; 4, APS with 1 biomarker; 5, APS with 2 biomarkers; 6, APS with 3 biomarkers. </plain></SENT>
<SENT sid="209" pm="."><plain>Colors are correlated with the positivity of the markers from negative (in black) to highly positive (in bright red). </plain></SENT>
<SENT sid="210" pm="."><plain>Gray boxes correspond to absence of data. </plain></SENT>
<SENT sid="211" pm="."><plain>This analysis reveals the close clustering of LA with anti-PS/PT IgG and IgM among APS patients, and with anti-PS/PT IgM alone among asymptomatic APA carriers (framed in yellow). </plain></SENT>
</text></p></caption><graphic xlink:href="fimmu-09-02971-g0004"/></fig></SecTag><p><text><SENT sid="212" pm="."><plain>A very strong correlation between the positivity for aPS/PT antibodies of IgM isotype and LA presence was observed (Table 3). </plain></SENT>
<SENT sid="213" pm="."><plain>Indeed, 35 out of 40 patients with LA (87.5%) were positive for aPS/PT of IgM isotype. </plain></SENT>
<SENT sid="214" pm="."><plain>When taking into account also IgG aPS/PT, 36 out for 40 patients with LA, were also positive for aPS/PT antibodies (90%). </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" position="float"><label>Table 3</label><caption><p><text><SENT sid="215" pm="."><plain>Correlation between LA and anti-PS/PT antibodies. </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>IgG anti-PS/PT </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain>IgM anti-PS/PT </plain></SENT>
</text></th><th valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>IgG and/or IgM anti-PS/PT </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>Sensitivity (%) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>50 (33.8–66.2) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>87.5 (73.2–95.8) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>90 (76.3–97.2) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>Specificity (%) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>100 (92.1–100) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain>91.1 (78.8–97.5) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>91.1 (78.8–97.5) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>PPV (%) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>100 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>89.7 (77.3–95.7) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>90 (77.8–95.8) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>NPV (%) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>69.2 (62.3–75.4) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="233" pm="."><plain>89.1 (78.2–94.9) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="234" pm="."><plain>91.1 (80.1–96.3) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="235" pm="."><plain>PLR </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="236" pm="."><plain>– </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="237" pm="."><plain>9.84 (3.83–25.27) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="238" pm="."><plain>10.12 (3.95–25.95) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="239" pm="."><plain>NLR </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>0.50 (0.37-0.68) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>0.14 (0.06–0.31) </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="242" pm="."><plain>0.11 (0.04–0.28) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain>Chi2 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>27.4 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>52.7 </plain></SENT>
</text></td><td valign="top" align="center" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>55.9 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><p><text><SENT sid="247" pm="."><plain>The performances of anti-PS/PT antibodies were calculated for all patients positive for LA. </plain></SENT>
</text></p><p><text><SENT sid="248" pm="."><plain>PPV, positive predictive value; NPV, negative predictive value; PLR, positive likelihood ratio; NLR, negative likelihood ratio; Chi2, chi square test. </plain></SENT>
</text></p></table-wrap-foot></table-wrap></SecTag></sec><sec><title><text><SENT sid="249" pm="."><plain>Non-conventional Markers in SNAPS </plain></SENT>
</text></title><p><text><SENT sid="250" pm="."><plain>Among the 17 patients with SNAPS, 9 were positive for at least 1 marker and 4 for more than 1 marker (Supplementary Table 2). </plain></SENT>
<SENT sid="251" pm="."><plain>Both IgG and IgM isotypes were detected in these patients. </plain></SENT>
<SENT sid="252" pm="."><plain>The markers found in SNAPS patients were PS/PT, PI, A5, and PT for IgG isotype and PS/PT, PA, PI, PS, A5, and PT for IgM isotype. </plain></SENT>
</text></p><p><text><SENT sid="253" pm="."><plain>IgG aPS/PT were found in 1 patient but they did not persist 12 weeks later. </plain></SENT>
<SENT sid="254" pm="."><plain>IgM aPS/PT were detected in 3 patients. </plain></SENT>
<SENT sid="255" pm="."><plain>However, in one of them the antibodies were not persistent; in the two others the persistence was not assessed. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s4"><title><text><SENT sid="256" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="257" pm="."><plain>This study aimed to explore the usefulness of several non-conventional APS markers for the diagnosis of APS, to assess whether they might play an additional role for the disease classification or for estimation of disease severity its severity. </plain></SENT>
<SENT sid="258" pm="."><plain>We have studied the presence and the persistence of IgA aβ2GP1 and IgG aβ2GP1 domain 1 and IgG and IgM directed against the PS/PT complex, and against phosphatidic acid (PA), phosphatidyl-ethanolamine (PE), phosphatidyl-glycerol (PG), phosphatidyl-inositol (PI), phosphatidylserine (PS), annexin V (A5), and prothrombin (PT) in a cohort of patients prospectively constituted. </plain></SENT>
<SENT sid="259" pm="."><plain>It comprised patients presenting with clinical APS, patients with a first episode of thrombosis and/or APS obstetric criterion but also patients classified as SNAPS and patients with at least one persistent positive APS marker without clinical manifestation. </plain></SENT>
</text></p><p><text><SENT sid="260" pm="."><plain>To date, aPS/PT antibodies are not included in the APS laboratory criteria but their positivity has been recently proposed as a part of the global APS score (GAPSS) (31, 32), and has been shown to be a strong prognostic factor for both arterial and venous thrombosis (33). </plain></SENT>
<SENT sid="261" pm="."><plain>Our data confirm the high prevalence of aPS/PT antibodies in APS patients (34). </plain></SENT>
<SENT sid="262" pm="."><plain>We found IgM and IgG aPS/PT in 65.8 and 43.9% of our APS patients, respectively, and their levels were correlated with the number of positive classical markers. </plain></SENT>
<SENT sid="263" pm="."><plain>All CAPS patients were found positive for IgG and IgM aPS/PT. </plain></SENT>
<SENT sid="264" pm="."><plain>However, we failed to correlate these antibodies positivity with the type of thrombosis presented by the patients. </plain></SENT>
</text></p><p><text><SENT sid="265" pm="."><plain>Interestingly, there was a striking positivity for IgM aPS/PT in the group of asymptomatic patients with APA (81.8%) whereas a positivity for IgG isotype was not frequent (18.2%). </plain></SENT>
<SENT sid="266" pm="."><plain>The majority of APA carriers in our study was detected by a pre-surgery assessment of coagulation tests and all were discovered positive firstly for LA. </plain></SENT>
<SENT sid="267" pm="."><plain>We found a very strong correlation between LA and aPS/PT IgM antibodies (chi-square test = 52.7) and this association was confirmed by our analysis by hierarchical clustering. </plain></SENT>
<SENT sid="268" pm="."><plain>Previously, it was shown that co-existence of these two parameters is frequent in APS patients (26). </plain></SENT>
<SENT sid="269" pm="."><plain>Atsumi et al have shown a strong correlation between the presence of aPS/PT antibodies of IgG and IgM isotypes and the presence of LA, whatever the detection method used (34). </plain></SENT>
<SENT sid="270" pm="."><plain>Our data confirm these findings but also reveal their co-existence in the group of asymptomatic APA carriers in which LA is mainly correlated with presence of IgM aPS/PT. </plain></SENT>
<SENT sid="271" pm="."><plain>This association might suggest that aPS/PT of IgM isotype may be less pathogenic than those of IgG isotype suggesting that the management of these patients in term of thrombosis prevention and follow up might be less strict. </plain></SENT>
</text></p><p><text><SENT sid="272" pm="."><plain>LA detection method is not accurate for patients treated by DOACs even at low concentration (35). </plain></SENT>
<SENT sid="273" pm="."><plain>Treatment with DOACs could give false positive results of LA with dilute Russel viper venom time (DRVVT) assay whereas activated partial thromboplastin time (APTT) assay is less influenced (23). </plain></SENT>
<SENT sid="274" pm="."><plain>It is especially important to be able to replace LA testing, when it could not be measured, with other suitable and similar marker as LA has been shown to be the strongest risk factor of thrombosis comparing to aCL and aβ2GP1 (36). </plain></SENT>
<SENT sid="275" pm="."><plain>Conventional APA (i.e., LA, aβ2GP, and aCL) triple positivity allows to identify the APS group of patients with persistence of APA (37) and especially with the highest risk of thrombosis or obstetric morbidity recurrence (38, 39). </plain></SENT>
<SENT sid="276" pm="."><plain>Thus, LA detection is crucial in case of thrombosis' recurrence during the treatment or if suspension of oral anticoagulation is considered (23). </plain></SENT>
<SENT sid="277" pm="."><plain>Unlike LA detection, anti-PS/PT antibodies are detectable by immunological assay which can be performed on small sample volume of serum or plasma and is not influenced by anti-thrombotic treatments. </plain></SENT>
</text></p><p><text><SENT sid="278" pm="."><plain>So, in these situations, aPS/PT antibodies (IgM and IgG) measuring could be considered to help to confirm or rule out the presence of LA (40). </plain></SENT>
</text></p><p><text><SENT sid="279" pm="."><plain>Despite technical progresses a consistent group of patients with clinical symptoms remains classified as “seronegative.” Recently, even a case of CAPS, has been reported in a patient negative for conventional biological markers (41). </plain></SENT>
<SENT sid="280" pm="."><plain>This emphasizes the persistent need of other biomarkers of APS. </plain></SENT>
<SENT sid="281" pm="."><plain>In this objective, we have tested a large panel of other autoantibodies. </plain></SENT>
<SENT sid="282" pm="."><plain>In contrast to previous studies (21–22, 42), we found aβ2GP1 D1 IgG and aβ2GP1 IgA positivity only in confirmed APS patients with double or triple positivity for conventional markers. </plain></SENT>
<SENT sid="283" pm="."><plain>These antibodies displayed an excellent specificity but quite low sensitivity and haven't shown any additional benefit as they were not positive in our group of SNAPS patients. </plain></SENT>
<SENT sid="284" pm="."><plain>One asymptomatic APA carrier exhibited a high positivity for aβ2GP1 D1 antibody. </plain></SENT>
<SENT sid="285" pm="."><plain>However, this patient had also a triple positivity for conventional APS markers and it was the only patient in this group positive for aPS/PT of IgG isotype. </plain></SENT>
<SENT sid="286" pm="."><plain>The clinical evolution of this specific patient needs to be carefully monitored. </plain></SENT>
</text></p><p><text><SENT sid="287" pm="."><plain>In our study, all patients positive for aβ2GP1 D1 IgG were positive for aPS/PT antibodies, confirming the correlation between these two markers previously shown by Nakamura et al. in APS patients (43). </plain></SENT>
</text></p><p><text><SENT sid="288" pm="."><plain>The absence of IgA aβ2GP1 positivity in our SNAPS patients contrary to the previous publications (21, 22, 44) may be explained by the small size of our cohort due to the design of our study which was prospective and monocentric, and the quite short period of observation. </plain></SENT>
<SENT sid="289" pm="."><plain>These antibodies were found only in a small number of studied patients: in about 3% of patients together with conventional antibodies but in &lt; 1% of patients in an isolated manner (44). </plain></SENT>
<SENT sid="290" pm="."><plain>This may suggest that detection of these antibodies could be helpful in quite limited cases. </plain></SENT>
</text></p><p><text><SENT sid="291" pm="."><plain>We found statistically significant difference in a frequency of non-conventional APS antibodies between patients and HD. </plain></SENT>
<SENT sid="292" pm="."><plain>These markers were particularly present in APS patients: from 2 to 7 markers per patient (or from 3 to 14 markers per patient if aPS/PT antibodies were taken into account, data not shown), with the highest number of markers in patients with CAPS. </plain></SENT>
<SENT sid="293" pm="."><plain>As a triple-positive APS characterizes a more severe disease comparing to the double or single positive APS, the positivity for multiple non-conventional markers could be another sign of the disease severity. </plain></SENT>
</text></p><p><text><SENT sid="294" pm="."><plain>We performed a hierarchical clustering of APS markers in patients to study possible association between some markers and patient profiles. </plain></SENT>
<SENT sid="295" pm="."><plain>As previously suggested, we observed a clusterization of LA and aPS/PT antibodies of IgM isotype in asymptomatic APA group and a clusterization of LA and aPS/PT antibodies of IgG isotype in APS patients. </plain></SENT>
<SENT sid="296" pm="."><plain>This emphasizes the potential pathogenicity of IgG aPS/PT antibodies. </plain></SENT>
<SENT sid="297" pm="."><plain>These data are in accordance with recently published study (40) which postulates the pathogenicity of the aPS/PT antibodies of IgG and not of IgM isotype in patients with APS secondary to lupus. </plain></SENT>
</text></p><p><text><SENT sid="298" pm="."><plain>In conclusion, our data obtained from a prospective cohort constituted mainly by patients with primary APS, demonstrate the potential value of aPS/PT antibodies as a strong marker of APS. </plain></SENT>
</text></p></sec></SecTag><SecTag type="AUTH_CONT"><sec id="s5"><title><text><SENT sid="299" pm="."><plain>Author Contributions </plain></SENT>
</text></title><p><text><SENT sid="300" pm="."><plain>EL performed the experiments and wrote the manuscript. </plain></SENT>
<SENT sid="301" pm="."><plain>LD designed the study, included the patients, and wrote the manuscript. </plain></SENT>
<SENT sid="302" pm="."><plain>AK performed the statistical analysis. </plain></SENT>
<SENT sid="303" pm="."><plain>YB performed some experiments and reviewed the manuscript. </plain></SENT>
<SENT sid="304" pm="."><plain>GdL included some patients and reviewed the manuscript. </plain></SENT>
<SENT sid="305" pm="."><plain>M-AD-D designed the study and wrote the manuscript. </plain></SENT>
</text></p><sec><title><text><SENT sid="306" pm="."><plain>Conflict of Interest Statement </plain></SENT>
</text></title><p><text><SENT sid="307" pm="."><plain>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. </plain></SENT>
</text></p></sec></sec></SecTag></body><back><SecTag type="SUPPL"><sec sec-type="supplementary-material" id="s6"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2018.02971/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2018.02971/full#supplementary-material</ext-link></p><supplementary-material content-type="local-data" id="SM1"><media xlink:href="Image_1.TIF"><caption><p><text><SENT sid="308" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM2"><media xlink:href="Image_2.TIF"><caption><p><text><SENT sid="309" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM3"><media xlink:href="Image_3.TIF"><caption><p><text><SENT sid="310" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM4"><media xlink:href="Image_4.TIF"><caption><p><text><SENT sid="311" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="SM5"><media xlink:href="Image_5.TIF"><caption><p><text><SENT sid="312" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag><SecTag type="REF"><ref-list><title>References</title><ref id="B1"><text><SENT sid="313" pm="."><plain>1.HughesGRHarrisNNGharaviAE. The anticardiolipin syndrome. J Rheumatol. (1986) 13:486–9. <?supplied-pmid 3735270?>3735270 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="314" pm="."><plain>2.MiyakisSLockshinMDAtsumiTBranchDWBreyRLCerveraR. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. (2006) 4:295–306. 10.1111/j.1538-7836.2006.01753.x<?supplied-pmid 16420554?>16420554 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="315" pm="."><plain>3.DurcanLPetriM Epidemiology of the antiphospholipid syndrome. </plain></SENT>
<SENT sid="316" pm="."><plain>In: CerveraREspinosaGKhamashtaMA editor. Antiphospholipid Syndrome in Systemic Autoimmune Diseases, 2nd Edn. Amsterdam: Elsevier (2016). p. 17–30. </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="317" pm="."><plain>4.TincaniAAndreoliLChighizolaCMeroniPL. The interplay between the antiphospholipid syndrome and systemic lupus erythematosus. Autoimmunity (2009) 42:257–9. 10.1080/08916930902827918<?supplied-pmid 19811269?>19811269 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="318" pm="."><plain>5.CerveraRPietteJ-CFontJKhamashtaMAShoenfeldYCampsMT. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. (2002) 46:1019–27. 10.1002/art.10187<?supplied-pmid 11953980?>11953980 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="319" pm="."><plain>6.AshersonRACerveraRPietteJCFontJLieJTBurcogluA. Catastrophic antiphospholipid syndrome. clinical and laboratory features of 50 patients. Medicine (1998) 77:195–207. 10.1097/00005792-199805000-00005<?supplied-pmid 9653431?>9653431 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="320" pm="."><plain>7.BucciarelliSCerveraREspinosaGGómez-PuertaJARamos-CasalsMFontJ. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors. Autoimmun Rev. (2006) 6:72–5. 10.1016/j.autrev.2006.06.007<?supplied-pmid 17138246?>17138246 </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="321" pm="."><plain>8.Ruiz-IrastorzaGCuadradoMJRuiz-ArruzaIBreyRCrowtherMDerksenR. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus (2011) 20:206–18. 10.1177/0961203310395803<?supplied-pmid 21303837?>21303837 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="322" pm="."><plain>9.ErkanDVegaJRamonGKozoraELockshinMD. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum. (2013) 65:464–71. 10.1002/art.37759<?supplied-pmid 23124321?>23124321 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="323" pm="."><plain>10.AshersonRACerveraRdeGroot PGErkanDBoffaMCPietteJC. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus (2003) 12:530–4. 10.1191/0961203303lu394oa<?supplied-pmid 12892393?>12892393 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="324" pm="."><plain>11.AndreoliLBertsiasGKAgmon-LevinNBrownSCerveraRCostedoat-ChalumeauN EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. </plain></SENT>
<SENT sid="325" pm="."><plain>(2017) 76:476–85. 10.1136/annrheumdis-2016-20977027457513 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="326" pm="."><plain>12.Alijotas-ReigJFerrer-OliverasRRuffattiATincaniALefkouEBerteroMT. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev. </plain></SENT>
<SENT sid="327" pm="."><plain>(2015) 14:387–95. 10.1016/j.autrev.2014.12.010<?supplied-pmid 25555817?>25555817 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="328" pm="."><plain>13.GrikaEPZiakasPDZintzarasEMoutsopoulosHMVlachoyiannopoulosPG. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol. (2012) 39:516–23. 10.3899/jrheum.110800<?supplied-pmid 22247356?>22247356 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="329" pm="."><plain>14.MekinianAAlijotas-ReigJCarratFCostedoat-ChalumeauNRuffattiALazzaroniMG on the behalf of the SNFMI and the European Forum on Antiphospholipid Antibodies. </plain></SENT>
<SENT sid="330" pm="."><plain>Refractory obstetrical antiphospholipid syndrome: Features, treatment and outcome in a European multicenter retrospective study. </plain></SENT>
<SENT sid="331" pm="."><plain>Autoimmun Rev. </plain></SENT>
<SENT sid="332" pm="."><plain>(2017) 16:730–4. 10.1016/j.autrev.2017.05.00628478081 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="333" pm="."><plain>15.AlessandriCContiFPendolinoMManciniRValesiniG. New autoantigens in the antiphospholipid syndrome. Autoimmun Rev. (2011) 10:609–16. 10.1016/j.autrev.2011.04.011<?supplied-pmid 21545849?>21545849 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="334" pm="."><plain>16.SugiTKatsunumaJIzumiSMcIntyreJAMakinoT. Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses. Fertil Steril. (1999) 71:1060–5. 10.1016/S0015-0282(99)00119-3<?supplied-pmid 10360910?>10360910 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="335" pm="."><plain>17.SakaiYAtsumiTIekoMAmengualOFurukawaSFurusakiA. The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum. (2009) 60:2457–67. 10.1002/art.24708<?supplied-pmid 19644870?>19644870 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="336" pm="."><plain>18.HughesGRKhamashtaMA. Seronegative antiphospholipid syndrome. Ann Rheum Dis. (2003) 62:1127. 10.1136/ard.2003.006163<?supplied-pmid 14644846?>14644846 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="337" pm="."><plain>19.NayfeRUthmanIAounJSaadAldin EMerashliMKhamashtaMA. Seronegative antiphospholipid syndrome. Rheumatology (2013) 52:1358–67. 10.1093/rheumatology/ket126<?supplied-pmid 23502076?>23502076 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="338" pm="."><plain>20.DeCraemer ASMusialJDevreeseKM Role of anti-domain 1-β2 glycoprotein I antibodies in the diagnosis and risk stratification of antiphospholipid syndrome. J Thromb Haemost. </plain></SENT>
<SENT sid="339" pm="."><plain>(2016) 14:1779–87. 10.1111/jth.1338927314634 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="340" pm="."><plain>21.Ruiz-GarcíaRSerranoMMartínez-FloresJÁMoraSMorillasLMartín-MolaMÁ. Isolated IgA anti- β2 glycoprotein I antibodies in patients with clinical criteria for antiphospholipid syndrome. J Immunol Res. </plain></SENT>
<SENT sid="341" pm="."><plain>(2014) 2014:704395. 10.1155/2014/704395<?supplied-pmid 24741618?>24741618 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="342" pm="."><plain>22.TortosaCCabrera-MaranteOSerranoMMartínez-FloresJAPérezDLoraD. Incidence of thromboembolic events in asymptomatic carriers of IgA anti ß2 glycoprotein-I antibodies. PLoS ONE (2017) 12:e0178889. 10.1371/journal.pone.0178889<?supplied-pmid 28727732?>28727732 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="343" pm="."><plain>23.HoxhaABanzatoARuffattiAPengoV. Detection of lupus anticoagulant in the era of direct oral anticoagulants. Autoimmun Rev. </plain></SENT>
<SENT sid="344" pm="."><plain>(2017) 16:173–8 10.1016/j.autrev.2016.12.010<?supplied-pmid 27988438?>27988438 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="345" pm="."><plain>24.PengoVRuffattiALegnaniCTestaSFierroTMarongiuF. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood (2011) 118:4714–8. 10.1182/blood-2011-03-340232<?supplied-pmid 21765019?>21765019 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="346" pm="."><plain>25.PengoVBiasioloAPegoraroCCucchiniUNoventaFIlicetoS. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. </plain></SENT>
<SENT sid="347" pm="."><plain>(2005) 93:1147–52. 10.1160/TH04-12-0839<?supplied-pmid 15968401?>15968401 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="348" pm="."><plain>26.PregnolatoFChighizolaCEncaboSShumsZNormanGLTripodiA. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res. (2013) 56:432–8. 10.1007/s12026-013-8421-z<?supplied-pmid 23572433?>23572433 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="349" pm="."><plain>27.PengoVTripodiAReberGRandJHOrtelTLGalliM. Update of the guidelines for lupus anticoagulant detection. </plain></SENT>
<SENT sid="350" pm="."><plain>Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. </plain></SENT>
<SENT sid="351" pm="."><plain>J Thromb Haemost. (2009) 7:1737–40 10.1111/j.1538-7836.2009.03555.x<?supplied-pmid 19624461?>19624461 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="352" pm="."><plain>28.R Core Team R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing (2018). </plain></SENT>
<SENT sid="353" pm="."><plain>Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.R-project.org/">https://www.R-project.org/</ext-link> </plain></SENT>
</text></ref><ref id="B29"><text><SENT sid="354" pm="."><plain>29.KassambaraA ggcorrplot: Visualization of a Correlation Matrix using ‘ggplot2’. </plain></SENT>
<SENT sid="355" pm="."><plain>R Package Version 0.1.2 (2018). </plain></SENT>
<SENT sid="356" pm="."><plain>Available online at: <ext-link ext-link-type="uri" xlink:href="https://CRAN.R-project.org/package=ggcorrplot">https://CRAN.R-project.org/package=ggcorrplot</ext-link> </plain></SENT>
</text></ref><ref id="B30"><text><SENT sid="357" pm="."><plain>30.SturnAQuackenbushJTrajanoskiZ. Genesis: cluster analysis of microarray data. Bioinformatics (2002) 18:207–8. 10.1093/bioinformatics/18.1.207<?supplied-pmid 11836235?>11836235 </plain></SENT>
</text></ref><ref id="B31"><text><SENT sid="358" pm="."><plain>31.OtomoKAtsumiTAmengualOFujiedaYKatoMOkuK. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. </plain></SENT>
<SENT sid="359" pm="."><plain>(2012) 64:504–12. 10.1002/art.33340<?supplied-pmid 21953404?>21953404 </plain></SENT>
</text></ref><ref id="B32"><text><SENT sid="360" pm="."><plain>32.SciasciaSSannaGMurruVRoccatelloDKhamashtaMABertolacciniML. GAPSS: the global anti-phospholipid syndrome score. Rheumatology (2013) 52:1397–403. 10.1093/rheumatology/kes388<?supplied-pmid 23315788?>23315788 </plain></SENT>
</text></ref><ref id="B33"><text><SENT sid="361" pm="."><plain>33.SciasciaSSannaGMurruVRoccatelloDKhamashtaMABertolacciniML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. </plain></SENT>
<SENT sid="362" pm="."><plain>A systematic review. Thromb Haemost. </plain></SENT>
<SENT sid="363" pm="."><plain>(2014) 111:354–64. 10.1160/TH13-06-0509<?supplied-pmid 24172938?>24172938 </plain></SENT>
</text></ref><ref id="B34"><text><SENT sid="364" pm="."><plain>34.AtsumiTIekoMBertolacciniMLIchikawaKTsutsumiAMatsuuraE. Association of autoantibodies against the phosphatidylserine–prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. (2000) 43:1982–93. 10.1002/1529-0131(200009)43:9 &lt; 1982::AID-ANR9&gt;3.0.CO;2-2<?supplied-pmid 11014348?>11014348 </plain></SENT>
</text></ref><ref id="B35"><text><SENT sid="365" pm="."><plain>35.RatzingerFLangMBelikSJilma-StohlawetzPSchmettererKGHaslacherH. Lupus-anticoagulant testing at NOAC trough levels. Thromb Haemost. (2016) 116:235–40. 10.1160/TH16-02-0081<?supplied-pmid 27075441?>27075441 </plain></SENT>
</text></ref><ref id="B36"><text><SENT sid="366" pm="."><plain>36.GalliMLucianiDBertoliniGBarbuiT. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood (2003) 102:2717–23. 10.1182/blood-2002-11-3334<?supplied-pmid 12816875?>12816875 </plain></SENT>
</text></ref><ref id="B37"><text><SENT sid="367" pm="."><plain>37.PengoVRuffattiADelRoss TTonelloMCuffaroSHoxhaA. Confirmation of initial antiphospholipid antibody positivity depends on the antiphospholipidantibody profile. J Thromb Haemost. (2013) 11:1527–31. 10.1111/jth.12264<?supplied-pmid 23601766?>23601766 </plain></SENT>
</text></ref><ref id="B38"><text><SENT sid="368" pm="."><plain>38.PengoVRuffattiALegnaniCGreselePBarcellonaDErbaN. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. (2010) 8:237–42. 10.1111/j.1538-7836.2009.03674.x<?supplied-pmid 19874470?>19874470 </plain></SENT>
</text></ref><ref id="B39"><text><SENT sid="369" pm="."><plain>39.RuffattiASalvanEDelRoss TGerosaMAndreoliLMainaA. Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. </plain></SENT>
<SENT sid="370" pm="."><plain>A European multicentre retrospective study. Thromb Haemost. </plain></SENT>
<SENT sid="371" pm="."><plain>(2014) 112:727–35. 10.1160/TH14-03-0191<?supplied-pmid 25008944?>25008944 </plain></SENT>
</text></ref><ref id="B40"><text><SENT sid="372" pm="."><plain>40.MarchettiTRibiCPernegerTTrendelenburgMHuynh-DoUdeMoerloose P. Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus. Rheumatology (2018) 57:1350–7. 10.1093/rheumatology/key095<?supplied-pmid 29672737?>29672737 </plain></SENT>
</text></ref><ref id="B41"><text><SENT sid="373" pm="."><plain>41.ContiFPrioriRAlessandriCMisasiRCapozziAPendolinoM. Diagnosis of catastrophic anti-phospholipid syndrome in a patient tested negative for conventional tests. Clin Exp Rheumatol. (2017) 35:678–80. <?supplied-pmid 28516871?>28516871 </plain></SENT>
</text></ref><ref id="B42"><text><SENT sid="374" pm="."><plain>42.deLaat BDerksenRHUrbanusRTdeGroot PG IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood (2005) 105:1540–5. 10.1182/blood-2004-09-338715507529 </plain></SENT>
</text></ref><ref id="B43"><text><SENT sid="375" pm="."><plain>43.NakamuraHOkuKAmengualOOhmuraKFujiedaYKatoM. First-line, non-criterial Antiphospholipid antibody testing for the diagnosis of Antiphospholipid syndrome in clinical practice: a combination of Anti-beta2-glycoprotein I Domain I, and Anti-Phosphatidylserine/Prothrombin complex antibodies tests. Arthritis Care Res. </plain></SENT>
<SENT sid="376" pm="."><plain>(2017) 70:627–34. 10.1002/acr.23310<?supplied-pmid 28686816?>28686816 </plain></SENT>
</text></ref><ref id="B44"><text><SENT sid="377" pm="."><plain>44.MurthyVWillisRRomay-PenabadZRuiz-LimónPMartínez-MartínezLAJatwaniS. Value of isolated IgA anti-β2-glycoprotein I positivity in the diagnosis of the antiphospholipid syndrome. Arthritis Rheum. </plain></SENT>
<SENT sid="378" pm="."><plain>(2013) 65:3186–93. 10.1002/art.38131<?supplied-pmid 23983008?>23983008 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
